Related Experiment Videos
Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in
J A Mitchell1, J R Batchelor, H Chapel
1University Department of Pharmacology, Oxford, UK.
Clinical and Experimental Immunology
|May 1, 1987
Summary
Reduced complement receptor 1 (CR1) expression is linked to hydralazine-induced lupus (Hz-SLE). This suggests impaired handling of circulating immune complexes (CIC) may increase susceptibility to developing this autoimmune condition.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Hydralazine is a medication used to treat high blood pressure.
- Hydralazine can induce a lupus-like syndrome (SLE) in some individuals.
- The mechanisms underlying hydralazine-induced SLE (Hz-SLE) susceptibility are not fully understood.
Purpose of the Study:
- To investigate the role of complement receptor 1 (CR1) expression in patients with a history of Hz-SLE.
- To examine the relationship between CR1 levels, circulating immune complexes (CIC), and susceptibility to Hz-SLE.
Main Methods:
- Family studies were conducted on 24 patients with a history of Hz-SLE who were clinically well.
- CR1 expression levels were measured and compared between Hz-SLE patients, their relatives, and normal individuals.
- Circulating immune complex (CIC) levels were assessed using a solid-phase Clq binding assay.
Main Results:
- Mean CR1 expression was significantly reduced (by 27%) in Hz-SLE patients compared to normal individuals.
- CR1 expression was also slightly reduced in relatives of Hz-SLE patients.
- Elevated CIC levels were observed in Hz-SLE patients, with an inverse correlation between CR1 and CIC levels.
Conclusions:
- Reduced CR1 expression is associated with a history of Hz-SLE.
- Impaired ability to efficiently clear CIC may contribute to susceptibility to developing Hz-SLE.
- CR1 levels and CIC levels remained stable over a 36-week study period in both patient and normal groups.